I think SNY's situation was different from Teva's currently. Lovenox patent was already expired, and SNY didn't know IF FDA was going to approve generic Lovenox at that time, thus no reason for SNY to file preemptive lawsuit against FDA because FDA approved generic at the same time it denied SNY's citizen petition, resulting SNY's lawsuit against FDA after the fact. Currently TEVA got its citizen petition denied before patent expiration and approval, with previous approval precedence from generic Lovenox, it isn't entirely surprising Teva filed lawsuit against FDA at this point because the other choice is to file another citizen's petition. My guess its purpose is to delay FDA approval of generic Copaxone as much as it can.
Market Data 
Markets 
AI
